Collagen News and Research RSS Feed - Collagen News and Research

Chemical compound shows promise in treating rheumatoid arthritis

Chemical compound shows promise in treating rheumatoid arthritis

Montana State University researchers and their collaborators have published their findings about a chemical compound that shows potential for treating rheumatoid arthritis. [More]
RepliCel's autologous cell treatment for Achilles tendinosis to be presented at ISCT 2015

RepliCel's autologous cell treatment for Achilles tendinosis to be presented at ISCT 2015

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today an upcoming poster presentation at the International Society for Cellular Therapy on RepliCel's autologous cell treatment for chronic Achilles tendinosis currently in a Phase 1/2 clinical trial. [More]
Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, supports efforts to bring the medical community the first ever treatment guidelines for Peyronie's Disease (PD), a condition in which collagen plaque, or scar tissue, develops on the shaft of the penis, and may harden and reduce flexibility. [More]
Researchers create tiny, complex scaffolds that can replace severely damaged eardrums

Researchers create tiny, complex scaffolds that can replace severely damaged eardrums

An international team of researchers has created tiny, complex scaffolds that mimic the intricate network of collagen fibres that form the human eardrum. [More]
DePuy Synthes CMF introduces SYNTHECEL Dura Repair for use in neurosurgery

DePuy Synthes CMF introduces SYNTHECEL Dura Repair for use in neurosurgery

DePuy Synthes CMF today announced the launch of SYNTHECEL Dura Repair, the first commercially available biosynthesized dural replacement derived from cellulose for use in neurosurgery. DePuy Synthes CMF is a part of the DePuy Synthes Companies of Johnson & Johnson. [More]
Scientists grow miniature human myelomas in shell-less chicken eggs to study multiple myeloma

Scientists grow miniature human myelomas in shell-less chicken eggs to study multiple myeloma

Multiple myeloma is an incurable cancer of the bone marrow. To date, no screening systems have been available to examine the effects of new drugs in a 3D environment. Researchers on the EU project OPTATIO might now fill this gap. They succeeded in growing miniature human myelomas in shell-less chicken eggs in order to screen new marine compounds for anti-myeloma activity. [More]
Researchers discover molecular mechanism that links breast tissue stiffness to tumor metastasis

Researchers discover molecular mechanism that links breast tissue stiffness to tumor metastasis

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have discovered a molecular mechanism that connects breast tissue stiffness to tumor metastasis and poor prognosis. The study, published April 20 in Nature Cell Biology, may inspire new approaches to predicting patient outcomes and halting tumor metastasis. [More]
Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse). [More]
TGen scientists discover the likely cause of rare type of muscle weakness in six children

TGen scientists discover the likely cause of rare type of muscle weakness in six children

Scientists at the Translational Genomics Research Institute (TGen), using state-of-the-art genetic technology, have discovered the likely cause of a child's rare type of severe muscle weakness. [More]
Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) and Cellular Dynamics International, Inc. (CEO: Robert J. Palay), a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that the two companies have entered into a definitive agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger. [More]
Experimental nanoparticle therapy speeds healing of all sorts of wounds

Experimental nanoparticle therapy speeds healing of all sorts of wounds

An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, which was successfully tested in mice, were published online in the Journal of Investigative Dermatology. [More]
UAB scientist explores the bone development function of runx2 gene

UAB scientist explores the bone development function of runx2 gene

Amjad Javed, Ph.D., of the University of Alabama at Birmingham, has taken a major step forward in understanding the bone development function of a gene called runx2, which could lead to future ways to speed bone healing, aid bone bioengineering, stem osteoporosis and reduce arthritis. [More]
Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. [More]
Plexin D1 gene determines body fat distribution in humans

Plexin D1 gene determines body fat distribution in humans

Scientists have known for some time that people who carry a lot of weight around their bellies are more likely to develop diabetes and heart disease than those who have bigger hips and thighs. [More]
Researchers identify promising new approach to treat pulmonary fibrosis

Researchers identify promising new approach to treat pulmonary fibrosis

By uncovering the mechanism by which fibrous tissue cells in the lung multiply, researchers at The Saban Research Institute of Children's Hospital Los Angeles, along with colleagues in Mexico and Canada, have identified a promising new approach for the treatment of pulmonary fibrosis. [More]
New strategy may ensure safety of adult epidermal stem cells before performing treatments

New strategy may ensure safety of adult epidermal stem cells before performing treatments

A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected and cultivated, genetically modified and single cells isolated before being rigorously tested to make sure they meet the highest possible safety criteria. [More]
Targeting stroma could potentially extend survival of pancreatic cancer patients

Targeting stroma could potentially extend survival of pancreatic cancer patients

Like a stealth jet cloaks itself from radar, cancer cells cloak themselves within tumors by hiding behind a dense layer of cellular material known as stroma. [More]
RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application (CTA) to the German Competent Authority, the Paul-Ehrlich-Institut (PEI), requesting clearance to initiate a Phase 1 clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin. [More]
MD Anderson awarded more than $22 million in research grants from CPRIT

MD Anderson awarded more than $22 million in research grants from CPRIT

The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas. Approximately half of the funds awarded for Individual Investigator Research Awards went to MD Anderson faculty as well as 40 percent of total IIRA awards that include those for children's and adolescent cancer and early detection and prevention. [More]
Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Nanometer-sized "drones" that deliver a special type of healing molecule to fat deposits in arteries could become a new way to prevent heart attacks caused by atherosclerosis, according to a study in pre-clinical models by scientists at Brigham and Women's Hospital and Columbia University Medical Center. [More]
Advertisement
Advertisement